| First Author | Verlande A | Year | 2021 |
| Journal | Sci Adv | Volume | 7 |
| Issue | 26 | PubMed ID | 34172439 |
| Mgi Jnum | J:315764 | Mgi Id | MGI:6815085 |
| Doi | 10.1126/sciadv.abf3885 | Citation | Verlande A, et al. (2021) Glucagon regulates the stability of REV-ERBalpha to modulate hepatic glucose production in a model of lung cancer-associated cachexia. Sci Adv 7(26) |
| abstractText | Lung adenocarcinoma is associated with cachexia, which manifests as an inflammatory response that causes wasting of adipose tissue and skeletal muscle. We previously reported that lung tumor-bearing (TB) mice exhibit alterations in inflammatory and hormonal signaling that deregulate circadian pathways governing glucose and lipid metabolism in the liver. Here, we define the molecular mechanism of how de novo glucose production in the liver is enhanced in a model of lung adenocarcinoma. We found that elevation of serum glucagon levels stimulates cyclic adenosine monophosphate production and activates hepatic protein kinase A (PKA) signaling in TB mice. In turn, we found that PKA targets and destabilizes the circadian protein REV-ERBalpha, a negative transcriptional regulator of gluconeogenic genes, resulting in heightened de novo glucose production. Together, we identified that glucagon-activated PKA signaling regulates REV-ERBalpha stability to control hepatic glucose production in a model of lung cancer-associated cachexia. |
